Amarin announces VAZKEPA receives regulatory approval in Switzerland

Amarin Corporation announced that Switzerland’s Swissmedic has granted approval to VAZKEPA. Swissmedic approved VAZKEPA to reduce risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides and established cardiovascular disease, or diabetes and at least one other cardiovascular risk factor. In parallel with the regulatory submission, Amarin had already initiated the process for obtaining national pricing and reimbursement in Switzerland, which is expected to conclude in the course of 2023. "This latest regulatory approval of VAZKEPA in Switzerland not only underscores the urgent need for proven therapies to help address residual cardiovascular risk for patients globally, it is also another example of an international health authority recognizing the value of our robust scientific evidence and innovative treatment to meet this need," said Steven Ketchum, PhD., President, Research & Development and Chief Scientific Officer, Amarin. The approval in Switzerland marks the sixth approval for the VASCEPA/VAZKEPA franchise within 2022.